Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
BörsenkürzelSRTS
Name des UnternehmensSensus Healthcare Inc
IPO-datumJun 03, 2016
CEOSardano (Joseph C)
Anzahl der mitarbeiter35
WertpapierartOrdinary Share
GeschäftsjahresendeJun 03
Addresse851 Broken Sound Pkwy NW Ste 215
StadtBOCA RATON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33487-3635
Telefon15619225808
Websitehttps://sensushealthcare.com/
BörsenkürzelSRTS
IPO-datumJun 03, 2016
CEOSardano (Joseph C)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten